CardiacNuclear / MolecularNews

Phase III REVEAL: Iodine-124 Evuzamitide PET Achieves 94% Sensitivity for Cardiac Amyloidosis

The Imaging Wiretoday

Iodine-124 evuzamitide PET/CT demonstrates 94% sensitivity and 94% NPV for cardiac amyloidosis, potentially serving as a first-line test to exclude the disease and avoid invasive biopsy, per Phase III REVEAL trial.

  • Specificity was 86% and positive predictive value was 85%.
  • High diagnostic accuracy observed in both AL and ATTR subtypes.
  • Bayer is moving toward discussions with the FDA and other health authorities for regulatory submissions.
Read the source

Also covered by

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.